Time to dismiss boost? Outcomes of children with localized and metastatic germinoma

Abstract

To determine long-term outcomes of a cohort of children with germinoma treated with chemotherapy and radiation therapy without primary tumor boost even in the absence of complete response to chemotherapy METHODS: This retrospective study analyzed the outcome of patients with germinoma consecutively diagnosed and treated at a tertiary care center from January 2000 to December 2021. MRIs were reviewed by two radiologists, blinded to patient data. Tumor location at diagnosis, tumor response to chemotherapy and at completion of radiation therapy and site of relapse were assessed. Tumor response was assessed radiologically by determining the tumor size and response on diffusion-weighted imaging, in addition to biochemical, cytological parameters and neurological status. Of 46 pediatric germinoma patients, 29 children (14 male; median age 12.8years) received no primary tumor boost. Median follow-up was 63months (range 9-187months). Twenty-five children had localized disease and tumor location was suprasellar (n = 11), pineal (n = 10), bifocal (n = 3) and basal ganglia (n = 1) while 4 children had metastatic disease at presentation. All patients completed multi-agent chemotherapy followed by either ventricular irradiation (VI) (23.4Gy) (n = 23), whole brain (WBI) (23.4Gy) (n = 5) or craniospinal radiation (CSI) (23.4Gy) (n = 1). Two children, who had localized disease at presentation and received VI after chemotherapy, relapsed 9months and 32months after completion of treatment respectively. No patient had a local relapse. Location of relapse was distant, outside (n = 1) and out- andinside (n = 1) the irradiation field. Five-year progression free survival (PFS) was 91% and overall survival (OS) was 100%. In this case series, excellent 5-year PFS and OS rates were achieved with chemotherapy followed by radiation therapy of 23.4Gy delivered without primary tumor boost. No local relapse was observed despite omitting primary tumor boost in patients with localized and metastatic germinoma.